Chemotargets

The company's business model initially centered on providing predictive analytics solutions and services to pharmaceutical companies, biotech firms, and research institutions. It generates revenue through the licensing of its software platforms and by offering consultancy services in drug safety, design, optimization, and repurposing. A significant milestone was the licensing of its CLARITY® technology, which defines the efficacy and safety profiles of new drugs, to the U.S. Food and Drug Administration (FDA). Recently, Chemotargets has initiated a strategic transformation to evolve into a biotechnology company that also develops its own novel medicines, with an initial focus on oncology. This transition involves forming strategic alliances with research centers to co-develop new therapies and create new spin-off entities.

Chemotargets' core offering is an integrated suite of software products and services designed to enhance the cost-efficiency and safety of new medicines. Its flagship platform, CLARITY®, is a key tool used by clients to assess the safety and efficacy profiles of drug candidates. The company has also developed ProSurfScan, an AI-driven technology that uses structure-based methods to identify and generate new bioactive molecules for therapeutic targets. This dual-platform approach allows for the simultaneous optimization of safety and efficacy. The company serves a range of personnel within client organizations, from medicinal chemists to clinical investigators. The services portfolio includes customized drug safety assessments, identifying new therapeutic uses for existing drugs (repurposing), and AI-driven drug design.